2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Treatment Considerations, Non-Biological Therapies, Anticoagulant Drugs, Clinical Practice (Health Services and Quality), Patient Safety, Quality Improvement, Quality of Care, Diseases, Bleeding and Clotting, Platelet Disorders, Thrombocytopenias, Thrombotic Disorders, Immunology, Infectious Diseases, Bacterial, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Study Population, Human, Adult, Pediatric
PAPER

4843 Unresolved indeterminate lupus anticoagulant results: Association with testing appropriateness and downstream anticoagulation

Ali Mushtaq, MBBS, Diana Arroyo Lugo2, Morayma Reyes Gil, MD, PhD3
1 Mayo Clinic, Jacksonville, Florida, United States
2 Cleveland Clinic, Cleveland, Ohio, United States
3 Cleveland Clinic, Cleveland, Ohio, United States

Introduction

Lupus anticoagulant (LA) testing is a multi-step clot-based algorithm whose interpretation depends on which patients are tested and under what conditions. Inappropriate antiphospholipid testing is well described, but existing audits characterize the request and the result and rarely evaluate what follows an indeterminate result, which may remain unresolved and is not directly addressed by classification frameworks. We examined whether appropriateness of the initial evaluation was associated with resolution on repeat testing, and what therapy followed.

Methods

Retrospective single-center cohort. Of 3,844 unique LA evaluations performed between January 2022 and December 2024, 261 were reported as indeterminate, defined as a prolonged screening test with a positive confirmatory step and correction of the screening time on a 1:1 mix with pooled normal plasma. Screen and confirm were interpreted against locally derived 99th-percentile cutoffs. Patients on a vitamin K antagonist or heparin were retained by design, since the frequency of such testing is itself a stewardship measure. The cohort comprised 111 adults with an index indeterminate result and repeat testing at 3 to 6 months; estimates therefore apply to patients who were retested. The primary endpoint was appropriate testing: an indication meeting ISTH-based patient-selection criteria in the absence of vitamin K antagonist or heparin exposure at collection; rheumatologic requests were considered concordant only with systemic lupus erythematosus (SLE). Secondary endpoints were resolution on repeat testing and new long-term anticoagulation not continued for an independent thrombotic indication. Comparisons used Fisher exact tests.

Results

Of the 111 patients, mean age was 48.4 years; 74 (66.7%) were female, 47 (42.3%) had prior thrombosis, and 8 (7.2%) had SLE. Only 44/111 index evaluations (39.6%; 95% CI 30.5-49.4) met the appropriate-testing definition. The indication failed selection criteria in 44/111 (39.6%), most often rheumatologic requests without SLE (n=22) or no documented indication (n=9), and was more common in outpatients than inpatients (41/83, 49.4% vs 3/28, 10.7%; p<0.001). Testing occurred during vitamin K antagonist or heparin exposure in 26/111 (23.4%), more often among inpatients than outpatients (11/28, 39.3% vs 15/83, 18.1%; p=0.037). Among evaluations not meeting the appropriate-testing definition, 34/67 (50.7%) remained indeterminate on repeat testing versus 12/44 (27.3%) of appropriate evaluations, an absolute difference of 23.5 percentage points (95% CI 4.8-39.6; p=0.018). Overall, 46/111 (41.4%) remained persistently indeterminate, 51/111 (45.9%) tested negative, and 14/111 (12.6%) confirmed LA positive. Long-term anticoagulation attributable to the workup was initiated in 19/111 patients (17.1%), more often among those whose result never resolved than among those retesting negative (12/46, 26.1% vs 3/51, 5.9%; p=0.010). Of these 19 patients, 15 (78.9%; 95% CI 54.4-93.9) never achieved laboratory confirmation of LA positivity: 12 remained persistently indeterminate and 3 tested negative. Seven of 111 patients (6.3%) were anticoagulated without ever meeting a laboratory classification criterion for APS. Among 14 patients with confirmed LA positivity on repeat testing, 4 (28.6%) were anticoagulated.

Conclusions

Fewer than half of indeterminate LA evaluations met criteria for appropriate initial testing, and inappropriate testing was nearly twice as likely to yield a result that never resolved. Most patients anticoagulated after this workup did not meet laboratory classification criteria for APS. This reflects discordance rather than error, since classification criteria are not diagnostic criteria and treatment decisions often incorporated prior arterial thrombosis. The practical implication is that the decision that matters most is made before the sample is drawn: an indeterminate result frequently persists, and once it exists it carries forward into indefinite anticoagulation. We recommend restricting LA testing to guideline-concordant indications and requiring documentation of anticoagulant status at order entry, so that fewer patients enter a diagnostic pathway that cannot resolve.

Ali Mushtaq, MBBS: No relevant conflicts of interest to declare.